FDA approves Tudorza Pressair for COPD

Share this article:
FDA approves Tudorza Pressair for COPD
FDA approves Tudorza Pressair for COPD

The Food and Drug Administration recently approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a serious lung disease that makes breathing difficult for many nursing home residents. COPD is the fourth leading cause of death in the United States. Symptoms can include chest tightness, chronic cough, and excessive phlegm.

Tudorza Pressair, a dry powder inhaler used twice daily, is a long-acting antimuscarinic agent that helps muscles around the large airways of the lungs stay relaxed to improve airflow.

“COPD is a serious disease that gets worse over time,” said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in FDA's Center for Drug Evaluation and Research. “The availability of long-term maintenance drugs for COPD provides additional treatment options for the millions of people who suffer with this debilitating disease.”

Share this article:

More in Products

Aviv REIT offers public stock

Aviv REIT announced the public offering of 8 million shares of common stock at a public offering price of $24.10 per share.

NCAL unveils 2014 Assisted Living Week logo

NCAL unveils 2014 Assisted Living Week logo

The National Center for Assisted Living is encouraging communities to use the 2014 "The Magic of Music" logo to celebrate National Assisted Living Week.

New healthcare educational catalog available

New healthcare educational catalog available

Nasco has released its 2014-2015 Health Care Educational Materials catalog, which focuses on training with versatile medical procedure simulators.